Versant Venture Management, LLC — 13F Holdings & Portfolio
CIK 1560009 · latest 13F-HR filed 2026-08-12
Versant Venture Management, LLC manages $162.6M in 13F-reported U.S. long-equity assets across 8 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are GLUE (47.34%), IPSC (18.33%), JBIO (13.55%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 0 new positions, exited 0, added to 5, and trimmed 2.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
SAN FRANCISCO, CA 94104
$162.6M
Long-equity book
8
Distinct positions
2026-06-30
Filed 2026-08-12
+0 / −0 / ↑5 / ↓2
vs 2026-03-31
| Name | Title / Status | Ownership | Type |
|---|
Top Adds (vs prior quarter)
- Monte Rosa Therapeutics, Inc.$24.7M +47.1%
- Century Therapeutics, Inc.$2.3M +8.4%
- Contineum Therapeutics, Inc.$1.8M +25.5%
- CRISPR Therapeutics AG$1.0M +14.7%
- Skye Bioscience, Inc.$158.0K +12.8%
Top Trims
- Lenz Therapeutics, Inc.-$9.2M -37.9%
- Tempest Therapeutics, Inc.-$143.0K -32.3%
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | Monte Rosa Therapeutics, Inc. | GLUE | 61225M102 | $77.0M | 47.34% | 3,180,780 | SH |
| 2 | Century Therapeutics, Inc. | IPSC | 15673T100 | $29.8M | 18.33% | 12,166,109 | SH |
| 3 | Jade Biosciences, Inc. | JBIO | 008064206 | $22.0M | 13.55% | 991,783 | SH |
| 4 | Lenz Therapeutics, Inc. | LENZ | 52635N103 | $15.1M | 9.28% | 2,656,888 | SH |
| 5 | Contineum Therapeutics, Inc. | CTNM | 21217B100 | $8.9M | 5.47% | 542,628 | SH |
| 6 | CRISPR Therapeutics AG | CRSP | H17182108 | $8.1M | 4.99% | 148,831 | SH |
| 7 | Skye Bioscience, Inc. | SKYE | 83086J200 | $1.4M | 0.86% | 2,007,704 | SH |
| 8 | Tempest Therapeutics, Inc. | TPST | 87978U108 | $299.4K | 0.18% | 269,772 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-06-30 | 2026-08-12 | $162.6M | 8 | 0001193125-26-347068 |
| 2026-03-31 | 2026-05-05 | $141.4M | 8 | 0001193125-26-206555 |
| 2025-12-31 | 2026-02-12 | $151.1M | 7 | 0001193125-26-048719 |